Ultragenyx Pharmaceutical (RARE) Interest Coverage Ratio Growth (5y) (2018 - 2026)
Ultragenyx Pharmaceutical (RARE) Interest Coverage Ratio Growth (5y) (2018 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,681.27 Bn | 66,680.98 Bn | - |
| 2 | Nanobiotix | 1,905.61 Bn | 1,905.55 Bn | - |
| 3 | Akari Therapeutics | 1,011.81 Bn | 1,011.81 Bn | - |
| 4 | BeOne Medicines | 467.29 Bn | 462.50 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.89 Bn | 115.65 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.28 Bn | 61.53 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.93 Bn | 62.93 Bn | - |
| 8 | Argenx Se | 55.90 Bn | 50.72 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.64 Bn | 34.63 Bn | 959.66 Mn |
| 10 | Ultragenyx Pharmaceutical | 2.73 Bn | 2.32 Bn | 106.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 8.66% |
| Dec 31, 2025 | 13.07% |
| Sep 30, 2025 | -15.55% |
| Jun 30, 2025 | -0.54% |
| Mar 31, 2025 | 7.31% |
| Dec 31, 2024 | -17.53% |
| Sep 30, 2024 | 30.98% |
| Jun 30, 2024 | 13.29% |
| Mar 31, 2024 | 26.79% |
| Dec 31, 2023 | -12.59% |
| Dec 31, 2022 | -28.99% |
| Dec 31, 2021 | -97.75% |
| Dec 31, 2020 | 47.02% |
| Sep 30, 2020 | 50.62% |
| Jun 30, 2020 | 48.29% |
| Dec 31, 2019 | 174.37% |
| Jun 30, 2019 | 39.74% |
| Mar 31, 2019 | -74.62% |
| Dec 31, 2018 | -51.36% |